ALT — Altimmune, Inc.

Summary of Altimmune Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Cash Position: As of September 30, 2025, total cash was $211 million, a 60% increase from the start of the year. The company raised $127 million in capital during the first nine months.
• R&D Expenses: Reported at $15 million for Q3 2025, down from $19.8 million in Q3 2024, attributed to timing of CRO costs. Key expenditures included $9.2 million for pemvidutide development.
• G&A Expenses: Increased to $5.9 million from $5 million year-over-year, driven by professional fees and stock-based compensation.
• Net Loss: Recorded at $19 million ($0.21 per share), improved from a net loss of $22.8 million ($0.32 per share) in Q3 2024.

2. Strategic Updates and Business Highlights:

• Pemvidutide Development: The company is preparing for a Phase III program for pemvidutide, focusing on MASH, AUD, and ALD. An end of Phase II meeting with the FDA is scheduled for Q4 2025.
• Clinical Trials: Enrollment for the RECLAIM Phase II trial in AUD was completed ahead of schedule, and the ALD trial (RESTORE) began enrollment in Q3.
• Leadership Expansion: New appointments include Dr. Christophe Arbet-Engels as Chief Medical Officer, Linda Richardson as Chief Commercial Officer, and Robin Abrahams as Chief Legal Officer.
• Upcoming Data: The company anticipates sharing 48-week data from the IMPACT trial before year-end, which is expected to further support pemvidutide's efficacy.

3. Forward Guidance and Outlook:

• Altimmune is optimistic about the upcoming 48-week data and its implications for the Phase III trial design. The company aims to maintain a flexible trial design to adapt to regulatory changes regarding endpoints.
• The management expressed confidence in the financial position to support ongoing development and commercialization efforts.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Risks: Although the FDA meeting is anticipated, the lack of 48-week data in discussions may pose a risk if the data does not meet expectations.
• Competitive Landscape: The emergence of other therapies, such as semaglutide and Lilly's Retatrutide, could create pricing pressures and affect market positioning.
• Market Acceptance: While early feedback from healthcare professionals is positive, the company must navigate potential payer pushback regarding pricing and reimbursement in a competitive MASH landscape.

5. Notable Q&A Insights:

• FDA Meeting: The end of Phase II meeting is based on 24-week data; 48-week data will be submitted later. Management believes the 24-week results are robust enough for regulatory discussions.
• NITs and AI Usage: There is increasing interest in using non-invasive tests (NITs) and AI for biopsy readings, which the company plans to incorporate into Phase III trials.
• RECLAIM Trial Insights: The primary endpoint focuses on the number of heavy drinking days per week. The rapid enrollment indicates strong interest and unmet needs in AUD.
• Competitive Positioning: Management believes pemvidutide's unique dual mechanism of action provides a competitive advantage over emerging therapies, particularly in MASH and AUD/ALD.

Overall, Altimmune is positioned for significant milestones in the coming months, with a strong financial foundation and promising clinical data, although it faces challenges from competition and regulatory uncertainties.